CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, NSC-79037) in the treatment of cancer. Phase II study.
D000230:Adenocarcinoma / Q000188:drug therapy; D000932:Antiemetics / Q000627:therapeutic use; D001853:Bone Marrow / Q000187:drug effects; D002214:Capsules; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D056486:Chemical and Drug Induced Liver Injury; D003510:Cyclohexanes; D005069:Evaluation Studies as Topic; D006801:Humans; D009325:Nausea / Q000139:chemically induced; D009369:Neoplasms / Q000188:drug therapy*; D009607:Nitrosourea Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced
D000932:Antiemetics; D002214:Capsules; D003510:Cyclohexanes; D009607:Nitrosourea Compounds